Vamil Divan

Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY)'s CM-214 data as overly pessimistic. The comment was based on the 3-percent pullback in the company's shares in after-hours trading Tuesday. However, at the time of writing, shares of Bristol-Myers Squibb were down 1....

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform...

Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant. On Thursday, Credit Suisse reinstated coverage of Johnson...

Previewing second-quarter results of Pfizer Inc. (NYSE: PFE), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to release its second-quarter results at 7 a.m. ET on Aug. 1. Analysts led by Vamil Divan expect...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), the world’s leading provider of generic pharmaceuticals, is allegedly poaching AstraZeneca plc (ADR) (NYSE: AZN) CEO Pascal Soriot, according to Wednesday reports from Israeli newspaper Calcalist. A Teva spokesperson declined to comment...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) hit a new 52-week low Wednesday for the second consecutive day as many investors found fault with the company's results from a phase 3 trial of its Eptinezumab therapy for the treatment of migraines. Piper Jaffray's Charles Duncan, Ph.D....

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced last Friday the FDA has approved Brvyxxa, its anti-coagulant candidate. Bevyxxa is an oral, once-daily Factor Xa inhibitor, was granted a Fast Track designation and approved under Priority review, which reduces the timeframe for review to...

Credit Suisse is bullish on Eli Lilly and Co (NYSE: LLY), saying the recent FDA delay on rheumatoid arthritis drug baricitinib is only a short-term setback for the pharma major. But, the brokerage acknowledges the stock could see some modest weakness on the news. Eli Lilly along with its partner...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced the FDA acceptance of the new drug application and European Medicines Agency validation of the marketing authorization for betrixaban for use in acute medically ill patients. With this news, the application’s probability of success has...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...

Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) from Neutral to Outperform, while lowering the target price from $59 to $52 (representing a 23 percent upside). Divan cited the company's selloff since May as the key reason for the upgrade, adding that...

Credit Suisse has lowered AbbVie Inc (NYSE: ABBV) to Neutral from Outperform, as it is “increasingly concerned about Humira's longevity given the more challenging payer environment and increasing calls for greater pricing transparency.” The downgrade follows the company’s...

Esperion Therapeutics Inc (NASDAQ: ESPR) reported encouraging top line results from its Phase 2 -035 and Phase 1 -037 trials, which Credit Suisse’s Vamil Divan believes addresses questions regarding the safety of combined bempedoic acid with high dose statins. Divan maintained an...

On September 16, Johnson & Johnson (NYSE: JNJ) announced plans to acquire Abbott Medical Optics for $4.325 billion in cash. Credit Suisse’s Vamil Divan maintains a Neutral rating on Johnson & Johnson, with a price target of $123. The Deal The deal is expected to close in Q1:17, and...